Last updated: 15 January 2020 at 1:41pm EST

Louis G Lange Net Worth




The estimated Net Worth of Louis G Lange is at least $10.5 Миллион dollars as of 23 December 2019. Louis Lange owns over 11,000 units of Gilead Sciences stock worth over $1,107,097 and over the last 16 years Louis sold GILD stock worth over $9,348,518.

Louis Lange GILD stock SEC Form 4 insiders trading

Louis has made over 14 trades of the Gilead Sciences stock since 2013, according to the Form 4 filled with the SEC. Most recently Louis sold 11,000 units of GILD stock worth $655,600 on 23 December 2019.

The largest trade Louis's ever made was selling 48,000 units of Gilead Sciences stock on 26 March 2018 worth over $1,386,720. On average, Louis trades about 11,510 units every 88 days since 2009. As of 23 December 2019 Louis still owns at least 13,678 units of Gilead Sciences stock.

You can see the complete history of Louis Lange stock trades at the bottom of the page.



What's Louis Lange's mailing address?

Louis's mailing address filed with the SEC is C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA STREET, 17TH FLOOR, SAN FRANCISCO, CA, 94108.

Insiders trading at Gilead Sciences

Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger и John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.



What does Gilead Sciences do?

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.



Complete history of Louis Lange stock trades at Cymabay Therapeutics Inc, Esperion Therapeutics и Gilead Sciences

инсайдер
Транзакция
Транзакция
Общая стоимость
Louis G Lange
Директор
Купить $198,996
1 Jul 2013


Gilead Sciences executives and stock owners

Gilead Sciences executives and other stock owners filed with the SEC include: